Annual report
4543.TEDINET S100TULJ
Period2023-04-01 → 2024-03-31
Filed2024-06-27
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥921.9bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥820.2bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥703.3bn | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥613.8bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥628.9bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥140.1bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥117.3bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥140.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥116.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥114.5bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥97.1bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥106.5bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥106.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥89.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥88.8bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥77.3bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥85.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥106.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥89.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥1.83T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.60T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.47T | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥1.35T | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥1.24T | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥504.3bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥491.2bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.33T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.11T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.01T | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.33T | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.11T | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.01T | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥856.7bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥754.8bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥204.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥187.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.3bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥200.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥166.9bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥146.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥117.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥141.5bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥121.5bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥117.5bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥81.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥59.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥78.5bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥85.3bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥84.7bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥62.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥86.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥70.9bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥7.4bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥14.0bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥71.5 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥59.5 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥58.72 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥51.16 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥56.98 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥71.47 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥59.48 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥58.69 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥51.05 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥56.31 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥893.8 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥746.07 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥669.23 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥566.57 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥501.68 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 72.5% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 69.3% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 68.7% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 63.4% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 60.8% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 8.7% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 8.4% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 9.5% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 9.6% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.7% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 30,591 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 30,207 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 28,294 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 26,482 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 26,438 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥399.8bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥375.0bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥341.4bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥316.4bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥319.0bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥77.0bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥67.8bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥110.7bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥91.1bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥79.4bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥65.3bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥80.1bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥112.0bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥99.7bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥87.9bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥79.0bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥62.8bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥52.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥65.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.44T | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥1.33T | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥1.28T | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.26T | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.15T | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥623.6bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥566.1bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥813.8bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥765.6bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥765.4bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥725.2bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥687.2bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥93.8bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥91.5bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥59.05 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥52.61 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥41.52 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥34.44 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥43.65 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥59.03 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥52.59 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥41.49 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥34.37 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥43.12 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥44 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥34 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥29 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥547.68 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥513.67 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥505.54 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥479.13 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥456.22 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 56.6% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.4% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.6% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.4% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.7% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 11.1% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.3% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.4% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.0% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 745,348,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 747,682,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 759,521,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 759,521,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 759,521,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 5,554 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 5,457 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 5,377 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 5,247 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 5,087 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥4.0bn |
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2024-03-31 | ¥248m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥3.2bn |
| Blood And Cell Technologies Companyreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥17.3bn |
| Blood And Cell Technologies Companyreportable segment | employees | at 2024-03-31 | 6386 pure |
| Blood And Cell Technologies Companyreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥168.3bn |
| Blood And Cell Technologies Companyreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥16.4bn |
| Cardiac And Vascular Companyreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥41.5bn |
| Cardiac And Vascular Companyreportable segment | employees | at 2024-03-31 | 16940 pure |
| Cardiac And Vascular Companyreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥555.7bn |
| Cardiac And Vascular Companyreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥123.8bn |
| Medical Care Solutions Companyreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥15.6bn |
| Medical Care Solutions Companyreportable segment | employees | at 2024-03-31 | 6038 pure |
| Medical Care Solutions Companyreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥197.6bn |
| Medical Care Solutions Companyreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥19.8bn |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥74.4bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥921.6bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥160.0bn |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥1.5bn |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2023-03-31 | ¥243m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥142m |
| Blood And Cell Technologies Companyreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥21.5bn |
| Blood And Cell Technologies Companyreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥147.6bn |
| Blood And Cell Technologies Companyreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥11.2bn |
| Cardiac And Vascular Companyreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥31.9bn |
| Cardiac And Vascular Companyreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥480.6bn |
| Cardiac And Vascular Companyreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥112.2bn |
| Medical Care Solutions Companyreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥20.9bn |
| Medical Care Solutions Companyreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥191.7bn |
| Medical Care Solutions Companyreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥14.8bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥74.3bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥820.0bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥138.2bn |
| Blood And Cell Technologies Companyreportable segment | employees | at 2024-03-31 | 260 pure |
| Cardiac And Vascular Companyreportable segment | employees | at 2024-03-31 | 1893 pure |
| Medical Care Solutions Companyreportable segment | employees | at 2024-03-31 | 2332 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,828
| Item | Context | Value | Unit |
|---|---|---|---|
| Segment profit loss IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 11163000000 | JPY |
| Segment profit loss IFRS | Prior1YearDuration_ReportableSegmentsMember | 138167000000 | JPY |
| Segment profit loss IFRS | Prior1YearDuration_ReconcilingItemsMember | -142000000 | JPY |
| Segment profit loss IFRS | Prior1YearDuration | 138025000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | -8951000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | － | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | -10020000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YearDuration_ReportableSegmentsMember | -18972000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YearDuration_ReconcilingItemsMember | 156000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YearDuration | -18816000000 | JPY |
| Non recurring profit or loss IFRS | Prior1YearDuration | -1876000000 | JPY |
| Operating profit loss IFRS | Prior1YearDuration | 117332000000 | JPY |
| Finance income IFRS | Prior1YearDuration | 2649000000 | JPY |
| Finance costs IFRS | Prior1YearDuration | 4016000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YearDuration | 171000000 | JPY |
| Profit loss before tax IFRS | Prior1YearDuration | 116137000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 35247000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 15927000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 18891000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YearDuration_ReportableSegmentsMember | 70066000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YearDuration_ReconcilingItemsMember | 171000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YearDuration | 70238000000 | JPY |
| Capital expenditures IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 31936000000 | JPY |
| Capital expenditures IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 20885000000 | JPY |
| Capital expenditures IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 21486000000 | JPY |
| Capital expenditures IFRS | Prior1YearDuration_ReportableSegmentsMember | 74308000000 | JPY |
| Capital expenditures IFRS | Prior1YearDuration_ReconcilingItemsMember | 1465000000 | JPY |
| Capital expenditures IFRS | Prior1YearDuration | 75774000000 | JPY |
| Revenue from external customers IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 555716000000 | JPY |
| Revenue from external customers IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 197569000000 | JPY |
| Revenue from external customers IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 168328000000 | JPY |
| Revenue from external customers IFRS | CurrentYearDuration_ReportableSegmentsMember | 921614000000 | JPY |
| Revenue from external customers IFRS | CurrentYearDuration_ReconcilingItemsMember | 248000000 | JPY |
| Revenue from external customers IFRS | CurrentYearDuration | 921863000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 123850000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 19789000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 16394000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_ReportableSegmentsMember | 160034000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_ReconcilingItemsMember | -3249000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration | 156785000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | -9553000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | － | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | -10642000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYearDuration_ReportableSegmentsMember | -20195000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYearDuration_ReconcilingItemsMember | 167000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYearDuration | -20028000000 | JPY |
| Non recurring profit or loss IFRS | CurrentYearDuration | 3339000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration | 140096000000 | JPY |
| Finance income IFRS | CurrentYearDuration | 3529000000 | JPY |
| Finance costs IFRS | CurrentYearDuration | 2775000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |